Katherine Boggs, PA
Medical · South Charleston, WVNPI 1295170587
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (31.5%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 35 manufacturers reported payments, led by Johnson & Johnson at 42.6% of the total. 2025 is the largest year on record at $14,415, 3.7 times the $3,939 reported in 2021. Among medical clinicians in WV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 440 payments — averaging $105.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$20K
- Actelion Pharmaceuticals US, Inc.$18K
- Regeneron Healthcare Solutions, Inc.$1K
- AstraZeneca$1K
- Boehringer Ingelheim$1K
- United Therapeutics Corporation$1K
- plus $4K from 29 others
What the payments were for
- Consulting fees$14,55631%
- Speaking & faculty fees$13,85530%
- Travel & lodging$8,23018%
- Food & beverage$9,17720%
- Education$4421%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 39 | $19,698 |
| Actelion Pharmaceuticals US, Inc. | 67 | $17,896 |
| Regeneron Healthcare Solutions, Inc. | 29 | $1,486 |
| AstraZeneca(2 entities) | 50 | $1,253 |
| Boehringer Ingelheim | 47 | $1,096 |
| United Therapeutics Corporation | 10 | $1,004 |
| GSK | 51 | $788 |
| Sanofi | 28 | $622 |
| Axsome Therapeutics, Inc. | 14 | $338 |
| Amgen | 15 | $263 |
| Insmed, Inc. | 12 | $249 |
| Verona Pharma, Inc. | 10 | $240 |
| Mylan Specialty L.p. | 10 | $192 |
| Jazz Pharmaceuticals Inc. | 9 | $164 |
| Harmony Biosciences LLC | 6 | $144 |
| Bayer | 1 | $125 |
| Genentech USA, Inc. | 7 | $100 |
| Sanofi-aventis U.S. LLC | 1 | $80 |
| Merck | 5 | $77 |
| Vifor Pharma, Inc. | 3 | $67 |
| Electromed, Inc. | 9 | $67 |
| Baxter Healthcare | 3 | $66 |
| Exeltis, USA Inc. | 2 | $33 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $27 |
| Optinose US, Inc. | 1 | $25 |
| Axonics, Inc. | 1 | $22 |
| Viatris Specialty LLC | 1 | $20 |
| Mallinckrodt Hospital Products Inc. | 1 | $18 |
| Eisai Inc. | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Philips North America LLC | 1 | $15 |
| Grifols USA, LLC | 1 | $15 |
| AbbVie | 1 | $14 |
| Hologic Sales And Service, LLC | 1 | $14 |
| La Jolla Pharmaceutical Company | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$46,261 in reported general payments places this provider in the 95th percentile of 233 medical providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 87 | $102,200 |
| Dupixent PenDupilumab | 16 | $61,433 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 23 | $21,995 |
| Breo ElliptaFluticasone/Vilanterol | 34 | $21,740 |
| SymbicortBudesonide/Formoterol Fumarate | 49 | $21,166 |
| Spiriva RespimatTiotropium Bromide | 26 | $16,349 |
| Spiriva HandihalerTiotropium Bromide | 14 | $9,000 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 30 | $7,324 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 119 | $6,239 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 22 | $5,441 |
| DuleraMometasone/Formoterol | 11 | $5,036 |
| Ventolin HfaAlbuterol Sulfate | 13 | $871 |
| Cefdinir | 34 | $518 |
| Fluticasone Propionate | 20 | $411 |
| Prednisone | 99 | $319 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $788 | $123,940121 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,253 | $43,16272 claims |
| Boehringer IngelheimSpiriva Respimat | $1,096 | $16,34926 claims |
| MerckDulera | $77 | $5,03611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 233 medical providers in West Virginia.
Other medical in South Charleston
- Katie CarpenterSouth Charleston$26K
- Kellie HanselSouth Charleston$12K
- Holli CaragSouth Charleston$7K
- Lauren ShafferSouth Charleston$6K
- Timothy DouglasSouth Charleston$6K
- Jacqueline McCartySouth Charleston$5K
- Anthony KnellSouth Charleston$4K
- Kelsey MathisSouth Charleston$3K
- Shelley GaumSouth Charleston$2K
- Lowell LarewMorgantown$31K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.